Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia

Plain-language summary

This study investigated the role of minimal residual disease (the very small number of disease cells remaining after treatment) in predicting the course of acute myeloid leukemia. It included patients over 18 with a diagnosis of acute myeloid leukemia who received intensive chemotherapy as first-line treatment. It was conducted as a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

A.O.U. Città della Salute e della Scienza

Start date

5/1/2015

Estimated completion

6/1/2015

Related genes

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of Acute Myeloid Leukemia
* Age \> 18 years
* Intensive chemotherapy as first line curative treatment
* Observation period: March 2004 - September 2014
* Bone marrow WT1 expression and Immunophenotyping by multi-parametric flow cytometry performed at baseline
* Written informed consent

Exclusion Criteria:

* Diagnosis of Acute Promyelocytic Leukemia
* Bone marrow WT1 expression and Immunophenotyping by multi-parametric flow cytometry NOT performed at baseline
* Patient ineligible to intensive chemotherapy